Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.4153
USD
|
-7.30%
|
|
-18.89%
|
-20.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
2,307
|
1,953
|
2,161
|
767.6
|
267.1
|
306.5
|
-
|
Enterprise Value (EV)
1 |
2,307
|
1,953
|
2,161
|
767.6
|
267.1
|
306.5
|
306.5
|
P/E ratio
|
-1.4
x
|
-4.58
x
|
-2.33
x
|
-0.49
x
|
-0.19
x
|
-0.11
x
|
-0.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
25.4
x
|
-
|
-
|
-
|
0.69
x
|
-
|
-
|
EV / Revenue
|
25.4
x
|
-
|
-
|
-
|
0.69
x
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-2,897,106
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,598
|
7,598
|
13,923
|
13,949
|
16,672
|
22,627
|
-
|
Reference price
2 |
10.15
|
9.150
|
5.600
|
1.800
|
0.5221
|
0.4153
|
0.4153
|
Announcement Date
|
3/18/20
|
4/22/21
|
3/25/22
|
3/24/23
|
4/12/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
90.69
|
-
|
-
|
-
|
387.1
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1,378
|
-463.3
|
-970.6
|
-1,451
|
-1,411
|
-2,023
|
-1,648
|
Operating Margin
|
-1,519.3%
|
-
|
-
|
-
|
-364.46%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-1,410
|
-477
|
-906
|
-1,554
|
-1,422
|
-2,135
|
-1,819
|
Net income
1 |
-1,421
|
-455.3
|
-898.2
|
-1,557
|
-1,427
|
-2,135
|
-1,819
|
Net margin
|
-1,567.2%
|
-
|
-
|
-
|
-368.5%
|
-
|
-
|
EPS
2 |
-7.250
|
-2.000
|
-2.400
|
-3.680
|
-2.690
|
-3.620
|
-2.420
|
Free Cash Flow
|
-796.2
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-877.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
4/22/21
|
3/25/22
|
3/24/23
|
4/12/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
381.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-223.9
|
-319.4
|
-349.3
|
-368.8
|
-329.5
|
-405.9
|
-557.2
|
-75.16
|
-338.3
|
-414.4
|
-372.5
|
-384.6
|
-384.6
|
-881.4
|
-379.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-19.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-238.6
|
-262.1
|
-379.9
|
-390.8
|
-349.2
|
-436.5
|
-588
|
-58.09
|
-314.3
|
-434.6
|
-399.2
|
-412.1
|
-412.9
|
-910.5
|
-420.1
|
Net income
1 |
-238.6
|
-262.1
|
-379.9
|
-390.8
|
-349.8
|
-438.9
|
-588.2
|
-59.94
|
-315.2
|
-435.9
|
-399.2
|
-412.1
|
-412.9
|
-910.5
|
-420.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-15.71%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.8000
|
-0.9500
|
-0.9500
|
-0.8000
|
-1.040
|
-1.290
|
-0.1100
|
-0.5600
|
-0.7900
|
-0.6100
|
-0.5400
|
-0.5300
|
-1.870
|
-0.5600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/26/21
|
3/25/22
|
4/27/22
|
8/12/22
|
10/28/22
|
3/24/23
|
4/28/23
|
8/11/23
|
10/27/23
|
4/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-796
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.09
|
0.14
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.1%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
4/22/21
|
3/25/22
|
3/24/23
|
4/12/24
|
-
|
-
|
Last Close Price
0.4153
USD Average target price
9.5
USD Spread / Average Target +2,187.50% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.46% | 9.4M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|